|
 |
| home > ebr > summer 2003 > losing our minds - what the future holds for the treatment of neurodegenerative disorders |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
| The words Alzheimer's or Parkinson's can strike terror in anyone's mind, particularly those of us aged over 50. With the average age of the western world's population rising, a disturbing flipside is that an increasing number of those that enter their 60s and beyond are falling victim to neurodegenerative conditions such as Alzheimer's, Parkinson's and stroke. Billions of dollars have been spent on developing novel effective treatments for these conditions with little success. More importantly, treatments that could actually modify the progress of these diseases rather than merely alleviate some of their symptoms, are urgently required. Demand for new and more effective drugs will therefore continue to intensify. Fortunately, there are now signs of light at the end of the tunnel and the near future could see significant progress in the battle to win back our minds. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Clinical Trials in CNS
25-26 November 2008, Copthorne Tara Hotel, London, UK
SMi present their 7th annual conference… Clinical Trials in CNS 25th to 26th November 2008, Copthorne Tara Hotel, London, UK
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
